• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CinCor Pharma Inc.

    2/14/23 2:30:54 PM ET
    $CINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CINC alert in real time by email
    SC 13G 1 d307602dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Cincor Pharma Inc.

    (Name of Issuer)

    Common Shares, $0.00001 par value per share

    (Title of Class of Securities)

    17240Y 109

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 17240Y 109

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Advisors LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,576,325

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,576,325

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,576,325

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.9%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA


    CUSIP No. 17240Y 109

     

      1    

      NAMES OF REPORTING PERSONS

     

      Joseph Edelman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,576,325

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,576,325

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,576,325

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.9%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 17240Y 109

     

      1    

      NAMES OF REPORTING PERSONS

     

      Perceptive Life Sciences Master Fund, Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      2,576,325

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      2,576,325

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,576,325

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.9%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    Item 1(a).

    Name of Issuer:

    Cincor Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    230 Third Avenue, 6th Floor

    Waltham, MA 02451

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Shares, $0.00001 par value per share (“Common Shares”)

     

    Item 2(e).

    CUSIP Number:

    17240Y 109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 43,764,323 outstanding Common Share as reported in the Issuer’s Form 10-Q filed on November 3, 2022.


    Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 2,576,325 Common Shares. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title:   Managing Member
    /s/ Joseph Edelman
    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title:   Managing Member
    Get the next $CINC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CINC

    DatePrice TargetRatingAnalyst
    12/7/2022$22.00Overweight
    Barclays
    11/29/2022Outperform → Perform
    Oppenheimer
    11/29/2022$60.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    10/28/2022$67.00Buy
    Goldman
    8/22/2022$73.00Overweight
    Piper Sandler
    2/1/2022Outperform
    Evercore ISI
    2/1/2022$30.00Outperform
    Oppenheimer
    2/1/2022$27.00Overweight
    Morgan Stanley
    More analyst ratings

    $CINC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on CinCor Pharma with a new price target

      Barclays initiated coverage of CinCor Pharma with a rating of Overweight and set a new price target of $22.00

      12/7/22 7:41:34 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CinCor Pharma downgraded by Oppenheimer

      Oppenheimer downgraded CinCor Pharma from Outperform to Perform

      11/29/22 7:31:01 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CinCor Pharma downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded CinCor Pharma from Overweight to Equal-Weight and set a new price target of $22.00 from $60.00 previously

      11/29/22 7:31:01 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by 5am Partners Vi, Llc

      4 - CinCor Pharma, Inc. (0001868734) (Issuer)

      2/28/23 4:29:55 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Healy James returned 19,608 shares to the company and sold $85,920 worth of shares (6,000 units at $14.32), closing all direct ownership in the company

      4 - CinCor Pharma, Inc. (0001868734) (Issuer)

      2/27/23 9:15:49 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Freeman Mason returned 40,000 shares to the company and sold $91 worth of shares (6 units at $15.21), closing all direct ownership in the company to satisfy withholding tax

      4 - CinCor Pharma, Inc. (0001868734) (Issuer)

      2/27/23 5:10:10 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)

      SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)

      3/3/23 10:06:48 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)

      SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)

      3/1/23 1:38:23 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)

      SC 13D/A - CinCor Pharma, Inc. (0001868734) (Subject)

      2/28/23 4:30:20 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CINC
    Financials

    Live finance-specific insights

    See more
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

      Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 trials expec

      11/28/22 7:30:00 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

      Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose Well-tolerated profile and differentiated mechanism of action supports combination approaches Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart A

      11/7/22 5:09:52 PM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CINC
    SEC Filings

    See more
    • CinCor Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

      8-K - CinCor Pharma, Inc. (0001868734) (Filer)

      2/24/23 9:19:58 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by CinCor Pharma Inc.

      25-NSE - CinCor Pharma, Inc. (0001868734) (Subject)

      2/24/23 9:07:22 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)

      SC 14D9/A - CinCor Pharma, Inc. (0001868734) (Subject)

      2/24/23 6:09:59 AM ET
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care